Advertisement
Document › Details
Biodesix, Inc.. (3/5/18). "Press Release: Biodesix Raises Add-On to Series G, Enters into Debt Refinancing Agreement with Innovatus Capital Partners, Scott Hutton Joins Biodesix". Boulder, CO.
Organisation | Biodesix Inc. | |
Organisation 2 | Innovatus Life Sciences Lending Fund I L.P. | |
Group | Innovatus Capital Partners (Group) | |
Product | VeriStrat® MS-based proteomic blood test | |
Product 2 | finance | |
Index term | Biodesix–SEVERAL: investment, 201803 financing round Series G add-on | |
Person | Hutton, Scott (Biodesix 201803– COO before Spectranetics + Medtronic) | |
Person 2 | Brunel, David (Biodesix 200810 CEO) | |
Scott Hutton Joins Biodesix as Chief Operating Officer, Bringing Two Decades of Medical Industry Experience to Management Team
Biodesix, Inc., a molecular diagnostics company that develops and commercializes non-invasive, blood-based diagnostic tests for oncology, today announced that the Company increased the size of its offering of its series G preferred shares in a follow-on sale and entered into a debt refinancing agreement with Innovatus Capital Partners to provide a $23 million term loan.
Biodesix will use the additional capital for the continued development of new blood-based diagnostic tests for clinical use with immunotherapies, as well as the continued expansion of the company’s offering of its commercialized VeriStrat® and GeneStrat® tests.
“We are pleased to add a new lender to our distinguished investor group,” said David Brunel, chief executive officer of Biodesix. “Innovatus Capital Partners has significant expertise in healthcare and a strong record in the diagnostic space and we are proud to have their backing.”
“We are proud to support Biodesix in its pursuit of providing innovative diagnostic tests for patients with lung cancer,” said Claes Ekstrom, managing director of Innovatus. “We look forward to forging a long-term relationship with the outstanding team at Biodesix as they continue to develop and provide solutions to save patient lives.”
Brunel added, “We are also excited to have Scott Hutton join our team as chief operating officer. Scott is an accomplished and strategic transformational leader with over nineteen years of experience in the medical device/technology industry, and he’s a great addition to our team.”
Scott Hutton was most recently the senior vice president and general manager of Spectranetics. Prior to Spectranetics, he served as vice president and general manager of the Neurosurgery unit of Medtronic and held several other positions with the company during his tenure. Hutton first joined Medtronic in 2000.
Biodesix, VeriStrat and GeneStrat are trademarks or registered trademarks of Biodesix, Inc. All other trademarks referenced herein are property of their respective owners.
About Biodesix
Biodesix® is a molecular diagnostics company advancing the development of innovative, multi-omic blood-based tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.
About Innovatus Life Sciences Lending Fund
Innovatus Life Sciences Lending Fund, I LP (“the Fund”) is an affiliate of Innovatus Capital Partners, LLC, an independent adviser and portfolio management firm with ~$1.6 billion in assets under management. Innovatus has a dedicated team of life sciences investment professionals with deep experience in healthcare, including life sciences. The Fund is currently focused on providing debt financing to medical device, diagnostic and biotechnology companies that address unmet medical needs, improve patient outcomes and reduce overall healthcare expenditures. Innovatus Capital Partners, LLC adheres to an investment strategy that identifies distressed, disruptive and growth opportunities in the less obvious market segments across multiple asset categories with a unifying theme of capital preservation, income generation, and upside optionality. Further information can be found at innovatuscp.com.
Record changed: 2023-06-05 |
Advertisement
More documents for Biodesix Inc.
- [1] Oncimmune Holdings plc. (6/28/19). "Press Release: Oncimmune Secures Strategic Commercialisation Agreement for EarlyCDT Lung in the US with Biodesix, Inc.". London....
- [2] MRM Proteomics Inc.. (1/28/19). "Press Release: MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics". Montréal, QC & Boulder, CO....
- [3] Biodesix, Inc.. (7/9/18). "Press Release: Biodesix Extends Lung Franchise with Acquisition of Integrated Diagnostics". Boulder, CO....
- [4] Biodesix, Inc.. (4/30/18). "Press Release: New Data Demonstrate the Biodesix VeriStrat Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions". Boulder, CO....
- [5] Biodesix, Inc.. (3/20/18). "Press Release: Biodesix Announces Biomarker Research Collaboration with Checkmate Pharmaceuticals"....
- [6] Biodesix, Inc.. (5/22/17). "Press Release: New Study Shows Advanced Diagnostic Tests, Including the VeriStrat Test, Can Help Physicians Improve Cancer Care Planning and Reach Quality Measures For Patients"....
- [7] Biodesix, Inc.. (4/5/17). "Press Release: Biodesix Presents Data from Three Studies at AACR Annual Meeting". Boulder, CO....
- [8] Biodesix, Inc.. (3/20/17). "Press Release: Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber. Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients"....
- [9] Biodesix, Inc.. (3/9/17). "Press Release: Biodesix and Progenetics Announce Distribution Agreement for Israel". Boulder, CO....
- [10] Biodesix, Inc.. (1/26/17). "Press Release: Clin-TOF Successfully Integrated into VeriStrat Workflow. Study Results, Presented at MSACL, Advance Biodesix/Bioyong Agreement"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top